Figure 6.

Safety evaluation of therapeutic regimen of aPD-L1 antibody combined with XAV-939. (A–H) The level of ALT (A), AST (B), r-GT (C), T-Bil (D), BUN (E), SCr (F), LDH-L (G), and CK-MB (H) in the serum of tumor-bearing mice at the endpoint of the therapeutic study illustrated in Figure 5A (n = 5, data presented as means ± SDs). (I) Representative H&E-stained images of heart, kidney, liver and lung from mice of each group at the endpoint of the therapeutic study illustrated in Figure 5A . Scale bar = 50 µm.